Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Media Farmasi Indonesia
Pramitaningastuti, Anastasia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Overview of Polypharmacy and Drug Interactions in Chronic Kidney Disease Patients at Siloam Hospitals Lippo Village Pramitaningastuti, Anastasia
Media Farmasi Indonesia Vol. 19 No. 1 (2024): Media Farmasi Indonesia
Publisher : SEKOLAH TINGGI ILMU FARMASI YAYASAN PHARMASI SEMARANG

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53359/mfi.v19i1.271

Abstract

Patients diagnosed with CKD in Indonesia have increased from 2% in 2013 to 3.8% in 2018. Polypharmacy is commonly found in CKD patients, especially in CKD patients with comorbidities. CKD with comorbidities will make the treatment more complex and expensive. This study was conducted to assess the relationship between polypharmacy and drug interactions in CKD patients. Data analysis was carried out descriptively on CKD patients at "X" Hospital in the period October to December 2022 and data were displayed in the form of tables and graphs. The results showed that the majority of patients with chronic kidney disease (CKD) were aged 46-65 years with 42 patients (50.0%). Chronic kidney disease (CKD) patients who get prescriptions for more than 5 drugs are 80 (95.2%) patients. Comorbidities that often occur in chronic kidney disease (CKD) patients are hypertension with 62 (19.62%) patients, diabetes mellitus with 29 (9.18%) patients, and coronary heart disease with 27 (8.54%) patients. From 84 patients, there were 626 potential drug interactions including 152 (24.28%) drug interactions with minor severity, 434 (69.33%) drug interactions with moderate severity, and 40 (6.39%) drug interactions with major severity. CKD patients who have one or more comorbidities will increase the risk of polypharmacy and an increased risk of drug interactions.
Variation in Time in Therapeutic Range (TTR) of Warfarin Use in Atrial Fibrillation Patients at Hospital X, Banten Pramitaningastuti, Anastasia; Benny Setiawan; Chelseata Ria Rebeka Br Sitepu
Media Farmasi Indonesia Vol. 20 No. 2 (2025): Media Farmasi Indonesia
Publisher : SEKOLAH TINGGI ILMU FARMASI YAYASAN PHARMASI SEMARANG

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53359/mfi.v20i2.345

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia in adults. Stroke, resulting from thromboembolism, is the most frequent and severe complication associated with atrial fibrillation, and its prevention is a primary therapeutic goal. Anticoagulant therapy is the cornerstone for stroke prevention, with warfarin being the most commonly used anticoagulant. However, warfarin therapy poses a significant risk of bleeding, necessitating regular and strict monitoring. The Time in Therapeutic Range (TTR) is a parameter used to assess the quality of warfarin therapy management, reflecting the percentage of time a patient's INR remains within the target therapeutic range of 2.0–3.0. To evaluate the variation of Time in Therapeutic Range (TTR) and its association with complications in atrial fibrillation patients receiving warfarin therapy. TTR was calculated using the Rosendaal interpolation method. The risk of bleeding complications was assessed using the HAS-BLED score, and stroke risk was evaluated using the CHA₂DS₂-VASc score. This retrospective observational study included 78 atrial fibrillation patients receiving warfarin, whose medical records were collected from January to June 2022. Data were presented in tables and charts and analyzed descriptively. The study found that only 15.38% (12 patients) achieved the target TTR (>70%), while 84.62% (66 patients) had suboptimal TTR levels. Most patients with low TTR scores had moderate to high HAS-BLED and CHA₂DS₂-VASc scores, indicating an increased risk of bleeding and stroke.
Co-Authors Benny Setiawan Chelseata Ria Rebeka Br Sitepu